WO2012118974A2 - Détection d'expression de rétrovirus endogène humain dans des cellules cancéreuses et des cellules saines - Google Patents
Détection d'expression de rétrovirus endogène humain dans des cellules cancéreuses et des cellules saines Download PDFInfo
- Publication number
- WO2012118974A2 WO2012118974A2 PCT/US2012/027289 US2012027289W WO2012118974A2 WO 2012118974 A2 WO2012118974 A2 WO 2012118974A2 US 2012027289 W US2012027289 W US 2012027289W WO 2012118974 A2 WO2012118974 A2 WO 2012118974A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- herv
- antibody
- nucleic acid
- cancer
- cell
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 68
- 201000011510 cancer Diseases 0.000 title claims abstract description 59
- 241000713887 Human endogenous retrovirus Species 0.000 title claims abstract description 6
- 238000001514 detection method Methods 0.000 title claims description 28
- 230000014509 gene expression Effects 0.000 title description 52
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 112
- 229920001184 polypeptide Polymers 0.000 claims abstract description 97
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 97
- 238000000034 method Methods 0.000 claims abstract description 74
- 150000007523 nucleic acids Chemical class 0.000 claims description 121
- 102000039446 nucleic acids Human genes 0.000 claims description 112
- 108020004707 nucleic acids Proteins 0.000 claims description 112
- 210000004027 cell Anatomy 0.000 claims description 82
- 239000000523 sample Substances 0.000 claims description 56
- 239000012472 biological sample Substances 0.000 claims description 36
- 239000013598 vector Substances 0.000 claims description 36
- 230000000295 complement effect Effects 0.000 claims description 27
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 23
- 230000027455 binding Effects 0.000 claims description 21
- 238000009739 binding Methods 0.000 claims description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims description 21
- 206010025323 Lymphomas Diseases 0.000 claims description 19
- 238000002965 ELISA Methods 0.000 claims description 15
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 12
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 11
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 11
- 206010033128 Ovarian cancer Diseases 0.000 claims description 11
- 239000013604 expression vector Substances 0.000 claims description 11
- 210000003296 saliva Anatomy 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 239000013068 control sample Substances 0.000 claims description 10
- 238000003364 immunohistochemistry Methods 0.000 claims description 10
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 9
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 claims description 9
- 238000004458 analytical method Methods 0.000 claims description 9
- 210000002966 serum Anatomy 0.000 claims description 9
- 231100000765 toxin Toxicity 0.000 claims description 9
- 239000003053 toxin Substances 0.000 claims description 9
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 7
- 206010060862 Prostate cancer Diseases 0.000 claims description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 7
- 208000010029 ameloblastoma Diseases 0.000 claims description 7
- 201000010881 cervical cancer Diseases 0.000 claims description 7
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 7
- 201000009030 Carcinoma Diseases 0.000 claims description 6
- 201000005787 hematologic cancer Diseases 0.000 claims description 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- 238000000684 flow cytometry Methods 0.000 claims description 5
- 238000003365 immunocytochemistry Methods 0.000 claims description 4
- 238000001114 immunoprecipitation Methods 0.000 claims description 4
- 238000001262 western blot Methods 0.000 claims description 4
- 210000002449 bone cell Anatomy 0.000 claims description 3
- 210000002889 endothelial cell Anatomy 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 238000010166 immunofluorescence Methods 0.000 claims description 3
- 230000002637 immunotoxin Effects 0.000 claims description 3
- 239000002596 immunotoxin Substances 0.000 claims description 3
- 231100000608 immunotoxin Toxicity 0.000 claims description 3
- 229940051026 immunotoxin Drugs 0.000 claims description 3
- 210000000663 muscle cell Anatomy 0.000 claims description 3
- 210000004498 neuroglial cell Anatomy 0.000 claims description 3
- 210000005259 peripheral blood Anatomy 0.000 claims description 3
- 239000011886 peripheral blood Substances 0.000 claims description 3
- 210000002826 placenta Anatomy 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 238000003018 immunoassay Methods 0.000 claims description 2
- 238000004393 prognosis Methods 0.000 claims description 2
- 238000003259 recombinant expression Methods 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000007899 nucleic acid hybridization Methods 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 18
- 108090000623 proteins and genes Proteins 0.000 description 65
- 102000004169 proteins and genes Human genes 0.000 description 41
- 235000018102 proteins Nutrition 0.000 description 40
- 108020004999 messenger RNA Proteins 0.000 description 36
- 125000003729 nucleotide group Chemical group 0.000 description 35
- 239000002773 nucleotide Substances 0.000 description 34
- 235000001014 amino acid Nutrition 0.000 description 28
- 229940024606 amino acid Drugs 0.000 description 27
- 150000001413 amino acids Chemical class 0.000 description 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 18
- 125000003275 alpha amino acid group Chemical group 0.000 description 17
- 239000000427 antigen Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 210000003719 b-lymphocyte Anatomy 0.000 description 13
- 125000005647 linker group Chemical group 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 108010076504 Protein Sorting Signals Proteins 0.000 description 12
- 239000012634 fragment Substances 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 241000283973 Oryctolagus cuniculus Species 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 108700012359 toxins Proteins 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 7
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 7
- 210000001280 germinal center Anatomy 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 230000001177 retroviral effect Effects 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000002741 palatine tonsil Anatomy 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 241001213909 Human endogenous retroviruses Species 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000286209 Phasianidae Species 0.000 description 3
- 239000013614 RNA sample Substances 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 108091070501 miRNA Proteins 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- -1 or haptens Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000701832 Enterobacteria phage T3 Species 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010060309 Glucuronidase Proteins 0.000 description 2
- 102000053187 Glucuronidase Human genes 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 108091005948 blue fluorescent proteins Proteins 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 206010016629 fibroma Diseases 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-O guanidinium Chemical compound NC(N)=[NH2+] ZRALSGWEFCBTJO-UHFFFAOYSA-O 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 108010093470 monomethyl auristatin E Proteins 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108700028325 pokeweed antiviral Proteins 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 210000002993 trophoblast Anatomy 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- RLMLFADXHJLPSQ-NPPFTVEMSA-N (3s,6s,9s,12s,15s,18s,21s,24r,27s)-3,6-dibenzyl-12,24-bis[(2r)-butan-2-yl]-15-(2-hydroxypropan-2-yl)-4,10,16,22-tetramethyl-18-(2-methylpropyl)-9,21-di(propan-2-yl)-13-oxa-1,4,7,10,16,19,22,25-octazabicyclo[25.3.0]triacontane-2,5,8,11,14,17,20,23,26-nonon Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(N(C)[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N(C)[C@H](C(=O)O[C@H](C(=O)N(C)[C@@H](C(C)C)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N1C)[C@H](C)CC)C(C)(C)O)=O)[C@H](C)CC)C1=CC=CC=C1 RLMLFADXHJLPSQ-NPPFTVEMSA-N 0.000 description 1
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100024321 Alkaline phosphatase, placental type Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108700003860 Bacterial Genes Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000271560 Casuariidae Species 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 241000271571 Dromaius novaehollandiae Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 241000272184 Falconiformes Species 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287227 Fringillidae Species 0.000 description 1
- 108700023863 Gene Components Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108010025815 Kanamycin Kinase Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- 108010036176 Melitten Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 241000287530 Psittaciformes Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 108020004688 Small Nuclear RNA Proteins 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000272534 Struthio camelus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010084455 Zeocin Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010008887 aureobasidin A Proteins 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000004395 cytoplasmic granule Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000804 electron spin resonance spectroscopy Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000007850 in situ PCR Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000007422 luminescence assay Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- VDXZNPDIRNWWCW-JFTDCZMZSA-N melittin Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(N)=O)CC1=CNC2=CC=CC=C12 VDXZNPDIRNWWCW-JFTDCZMZSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000009894 physiological stress Effects 0.000 description 1
- 108010031345 placental alkaline phosphatase Proteins 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 108010037253 syncytin Proteins 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000006226 wash reagent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Definitions
- HERVs Human endogenous retroviruses
- HERVs had integrated into the human genome millions of year ago, some HERV genes still have open reading frames (ORFs) and thus can potentially code for protein.
- ORFs open reading frames
- HERV-W expression has been detected in lung, gastric, ovarian and bladder cancers, and HERV-W has been reported to induce ⁇ 16 biased T cell response when presented as "multiple sclerosis retroviral particles.”
- GC germinal center
- vSAg29 retroviral superantigen
- mtv29 endogenous mouse mammary tumor virus
- Lymphoma-host CD4 T cell interaction was observed in which the lymphoma cells stimulated syngeneic response in PBL CD4 T cells, resulting in BV23 oligoclonality (92% of BV23 had the same CDR3 length as observed for the lymphoma- containing CD4 T cells).
- the invention generally relates to human endogenous retrovirus env (HERV- WL) polypeptides, nucleotide sequences, HERV-WL antibodies, methods to detect cancer, and methods to determine the effectiveness of the treatment of cancer.
- HERV- WL human endogenous retrovirus env
- the invention provides an isolated antibody that specifically binds to a human endogenous env polypeptide (HERV-WL).
- the antibody binds to an epitope comprising the sequence TEKVEIRDGIQRRA (SEQ ID NO:2).
- the antibody may be a monoclonal, polyclonal, humanized, or human antibody.
- the antibody may also be conjugated to a detectable label and/or a toxin.
- the invention provides a method of delivering a toxin to a cell that expresses HERV-WL comprising contacting a cell with an isolated antibody that specifically binds to HERV-WL, wherein the antibody is conjugated to a toxin.
- the invention provides a method of detecting HERV-WL in a cell comprising contacting a cell with an isolated antibody that specifically binds to HERV-WL and detecting the presence of a complex of the antibody and HERV-WL; wherein the presence of the complex is indicative of the detecting of HERV-WL in the cell.
- the cell may be a bone cell, muscle cell, placenta cell, endothelial cell, epithelial cell, epidermoid cell, glial cell, tumor cell, or a cancer cell.
- the detection is performed by immunoassay, ELISA, immunoprecipitation,
- the invention provides a method of detecting a cancer in a subject comprising determining a level of HEVR-WL or a nucleic acid encoding HERV- WL in a biological sample from the subject; comparing the level detected in the subject's sample to a standard level in a control sample; and determining that a cancer is present if the level in the subject's sample is greater than the standard level in the control sample.
- the level of HERV-WL may be detected by an antibody that specifically binds to HERV-WL.
- the level of the nucleic acid encoding HERV-WL is determined by detecting binding of the nucleic acid to a second nucleic acid which is at least 85% identical to SEQ ID NO: l or complement thereof, or a third nucleic acid that encodes a polypeptide that is at least 85% identical to the sequence of SEQ ID NO:2 or the complement thereof.
- the cancer may be a blood cancer, lymphoma, B cell lymphoma, non-Hodgkin's lymphoma, diffuse large B cell lymphoma, Burkitt' s lymphoma, ameloblastoma, carcinomas including squamous cell carcinoma, mucoepidermoid carcinoma, ovarian cancer, cervical cancer, prostate cancer and breast cancer.
- the biological sample may be peripheral blood and/or saliva.
- the invention provides a method for determining the effectiveness of a treatment in a subject suffering from cancer comprising, obtaining a pretreatment biological sample from a subject, obtaining a post treatment biological sample from the subject, detecting the level of HERV-WL present in the samples;
- the level of HERV-WL in the pretreatment biological sample is determined to be effective if the HERV-WL polypeptide present in the post-treatment biological sample is decreased compared to the HERV-WL level present in the pretreatment sample.
- the level of HERV-WL may be detected by an antibody that specifically binds to HERV-WL.
- the level of the nucleic acid encoding HERV-WL is determined by detecting binding of the nucleic acid to a second nucleic acid which is at least 85% identical to SEQ ID NO: l or complement thereof, or a third nucleic acid that encodes a polypeptide that is at least 85% identical to the sequence of SEQ ID NO:2 or the complement thereof.
- the cancer may be a blood cancer, lymphoma, B cell lymphoma, non-Hodgkin's lymphoma, diffuse large B cell lymphoma, Burkitt' s lymphoma, ameloblastoma, carcinomas including squamous cell carcinoma,
- the invention provides an isolated nucleic acid which is at least 85% identical to SEQ ID NO: 1.
- the nucleic acid hybridizes to SEQ ID NO: l under high stringency conditions.
- the invention provides an isolated nucleic acid comprising a sequence that encodes a peptide sequence that is at least 85% identical to SEQ ID NO:2.
- the nucleic acid hybridizes to SEQ ID NO:2 under high stringency conditions.
- the invention provides an isolated polypeptide encoded by an isolated nucleic acid which is at least 85% identical to SEQ ID NO: 1.
- the polypeptide is encoded by an isolated nucleic acid that hybridizes to SEQ ID NO: l under high stringency conditions.
- the invention provides an isolated polypeptide comprising a sequence which is as least 99% identical to SEQ ID NO:2.
- the invention provides a recombinant vector comprising an isolated nucleic acid which is at least 85% identical to SEQ ID NO: 1.
- the recombinant vector may comprise a nucleic acid that hybridizes to SEQ ID NO: 1 under high stringency conditions.
- the recombinant vector may comprise a nucleic acid that hybridizes to SEQ ID NO:2 under high stringency conditions.
- the recombinant vector is a recombinant expression vector.
- the invention provides an array that comprises a solid support having a plurality of locations and a nucleic acid which is at least 85% identical to SEQ ID NO: 1, a nucleic acid that hybridizes to SEQ ID NO: l under high stringency conditions or a nucleic acid that hybridizes to SEQ ID NO:2 under high stringency conditions, attached to the locations.
- the invention provides a host comprising a recombinant vector that contains a nucleic acid which is at least 85% identical to SEQ ID NO: 1, a nucleic acid that hybridizes to SEQ ID NO: 1 under high stringency conditions or a nucleic acid that hybridizes to SEQ ID NO:2 under high stringency conditions.
- the invention provides a kit for performing the methods of the invention.
- Fig. 1 illustrates the relative expression of HERV-W mRNA (normalized to that of TBP mRNA expression) + SEM in normal tonsilar low density (“activated") B cells (40/50% percol gradient interphase, Tonsil low 8 ) as measured by Real-Time
- Fig. 2 illustrates the relative transcription of HERV-W in normal and lymphoma B cells as measured by Real-Time Quantitative PCR.
- FIG. 3 depicts specificity of HERV-WL detection.
- ELISA plates were coated with equal concentrations of HERV-WL protein or control bovine serum Albumin (BSA), horse Ig, and normal rabiit Ig (NL Rblg).
- BSA bovine serum Albumin
- horse Ig horse Ig
- normal rabiit Ig NL Rblg
- Fig. 4 depicts the detection of HERV-WL protein in serum samples from normal and cancer patients.
- Fig. 5 depicts the detection of HERV-WL protein in saliva samples from normal and cancer patients.
- Fig. 6 is the Predicted Amino-acid translations of HERV-WL env, western blot analysis also shows two conforming major bands.
- Fig. 6A is Frame 1 of HERV-WL env;
- Fig. 6B is Frame 2 of HERV-WL env.
- This invention is based, at least in part, on unexpected discoveries of a novel human endogenous retroviral env gene, HERV-WL. Novel HERV-WL polypeptides, nucleotide sequences and HERV-WL antibodies that are useful in methods to detect cancer, and methods to determine the effectiveness of the treatment of cancer.
- HERV-WL means a novel human endogenous retroviral gene that is substantially identical and complementary to SEQ ID NO: l, and refers to all isoforms and variants of a HERV-WL polypeptide and the polynucleotide that encodes the HERV-WL polypeptide.
- antibody refers to an immunoglobulin or antigen-binding fragment thereof, and encompasses any such polypeptide comprising an antigen-binding fragment of an antibody.
- antibody also includes antigen-binding fragments of an antibody.
- antigen-binding fragments include, but are not limited to, Fab fragments (consisting of the V L , V H , C L and C H I domains); Fd fragments (consisting of the V H and C H I domains); Fv fragments (referring to a dimer of one heavy and one light chain variable domain in tight, non-covalent association); dAb fragments (consisting of a V H domain); single domain fragments (V H domain, V L domain, V HH domain, or V NAR domain); isolated CDR regions; (Fab') 2 fragments, bivalent fragments (comprising two Fab fragments linked by a disulphide bridge at the hinge region), scFv (referring to a fusion of the V L and V H domains, linked together with a short linker), and other antibody fragments that retain antigen-binding function.
- Fab fragments consisting of the V L , V H , C L and C H I domains
- Fd fragments consististing of the V H
- amino acid refers to natural and/or unnatural or synthetic amino acids, including glycine and both the D and L optical isomers, amino acid analogs (for example norleucine is an analog of leucine) and peptidomimetics.
- Animal includes all vertebrate animals including humans.
- vertebrate animal includes, but not limited to, mammals, humans, canines (e.g., dogs), felines (e.g., cats); equines (e.g., horses), bovines (e.g., cattle), porcine (e.g., pigs), mice, rabbits, goats, as well as in avians.
- avian refers to any species or subspecies of the taxonomic class ava, such as, but not limited to, chickens (breeders, broilers and layers), turkeys, ducks, a goose, a quail, pheasants, parrots, finches, hawks, crows and ratites including ostrich, emu and cassowary.
- Array refers to a solid support having a plurality of locations to attach a nucleotide sequence such as a probe or an antibody.
- Attached or “immobilized' as used herein to refer to a probe or an antibody and a solid support refers to the binding between a probe or an antibody and the solid support is sufficient to be stable under conditions of binding, washing, analysis, and removal.
- the binding may be covalent or non-covalent. Covalent bonds may be formed directly between the probe and the solid support or may be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules.
- Non-covalent binding may be one or more of electrostatic, hydrophilic, and hydrophobic interactions.
- non-covalent binding is the covalent attachment of a molecule, such as streptavidin, to the support and the non-covalent binding of a biotinylated probe to the streptavidin. Immobilization may also involve a combination of covalent and non-covalent interactions.
- the "solid substrate" used for the array may be in the form of beads, particles or sheets, and may be permeable or impermeable, depending on the type of array, wherein the surface is coated with a suitable material enabling binding of the binding reagents at high affinity.
- the surface may be in the form of beads or particles, fibers (such as glass wool or other glass or plastic fibers) or glass or plastic capillary tubes.
- the solid surface may be in the form of plastic, micromachined chips, membranes, slides, plates or sheets in which at least one surface is substantially flat, wherein these surfaces may comprise glass, plastic, silicon, low cross-linked and high cross-linked polystyrene, silica gel, polyamide, and the like.
- Biological sample as used herein means a sample of biological tissue or fluid that comprises polypeptides and/or nucleic acids. Such samples include, but are not limited to, tissue isolated from animals. Biological samples may also include sections of tissues such as biopsy and autopsy samples, frozen sections taken for histologic purposes, blood, plasma, serum, sputum, saliva, stool, tears, mucus, hair, and skin. Biological samples also include explants and primary and/or transformed cell cultures derived from patient tissues. A biological sample may be provided by removing a sample of cells from an animal, but can also be accomplished by using previously isolated cells (e.g., isolated by another person, at another time, and/or for another purpose), or by performing the methods of the invention in vivo.
- tissue isolated from animals include, but are not limited to, tissue isolated from animals. Biological samples may also include sections of tissues such as biopsy and autopsy samples, frozen sections taken for histologic purposes, blood, plasma, serum, sputum, saliva, stool, tears, mucus, hair, and skin.
- biopsy and “biopsy tissue” refer to a sample of tissue or fluid that is removed from a subject for the purpose of determining if the sample contains cancerous tissue. In some embodiments, biopsy tissue or fluid is obtained because a subject is suspected of having cancer, and the biopsy tissue or fluid is then examined for the presence or absence of cancer.
- cancer cell and “tumor cell”, and grammatical equivalents refer to the total population of cells derived from a tumor, a cancer or a pre-cancerous lesion.
- “Complement” or “complementary” as used herein means Watson-Crick or Hoogsteen base pairing between nucleotides or nucleotide analogs of nucleic acid molecules.
- amino acid variants refers to amino acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated (e.g., naturally contiguous) sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine.
- nucleic acid variations are "silent variations", which are one species of conservatively modified variations.
- Every nucleic acid sequence herein which encodes a polypeptide also describes silent variations of the nucleic acid.
- each codon in a nucleic acid except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan
- TGG which is ordinarily the only codon for tryptophan
- amino acid sequences one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a "conservatively modified variant", including where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art.. Guidance concerning which amino acid changes are likely to be phenotypically silent can also be found in Bowie et al., 1990, Science 247: 1306 1310.
- Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles.
- Typical conservative substitutions include but are not limited to: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).
- Amino acids can be substituted based upon properties associated with side chains, for example, amino acids with polar side chains may be substituted, for example, Serine (S) and Threonine (T); amino acids based on the electrical charge of a side chains, for example, Arginine (R) and Histidine (H); and amino acids that have hydrophobic side chains, for example, Valine (V) and Leucine (L).
- changes are typically of a minor nature, such as conservative amino acid substitutions that do not significantly affect the folding or activity of the protein.
- humanized antibody and “engineered antibody”, as used herein, is intended to include antibodies having variable region frameworks derived from sequences of human origin. Furthermore, if the antibody contains a constant region, the constant region is typically derived from such human sequences, e.g., human germline sequences, or naturally occurring (e.g., allotypes) or mutated versions of human germline sequences.
- the humanized antibodies of the invention may include amino acid residues not encoded by human sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo).
- epitope refers to a site on an antigen to which B and/or T cells respond or a site on a molecule against which an antibody will be produced and/or to which an antibody will bind.
- an epitope can be recognized by an antibody defining the epitope.
- An epitope can be either a "linear epitope” (where a primary amino acid primary sequence comprises the epitope; typically at least 3 contiguous amino acid residues, and more usually, at least 5, and up to about 8 to about 10 amino acids in a unique sequence) or a "conformational epitope" (an epitope wherein the primary, contiguous amino acid sequence is not the sole defining component of the epitope).
- a conformational epitope may comprise an increased number of amino acids relative to a linear epitope, as this conformational epitope recognizes a three-dimensional structure of the peptide or protein. For example, when a protein molecule folds to form a three dimensional structure, certain amino acids and/or the polypeptide backbone forming the conformational epitope become juxtaposed enabling the antibody to recognize the epitope.
- Methods of determining conformation of epitopes include but are not limited to, for example, x-ray crystallography, two-dimensional nuclear magnetic resonance spectroscopy and site-directed spin labeling and electron paramagnetic resonance spectroscopy. See, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, Glenn E. Morris, Ed. (1996), the disclosure of which is incorporated in its entirety herein by reference.
- a "fusion polypeptide” refers to a polypeptide created through the joining of two or more heterologous proteins or polypeptides.
- a heterologous protein, polypeptide, nucleic acid, or gene is one that originates from a foreign species, or, if from the same species, is substantially modified from its original form. Two fused domains or sequences are heterologous to each other if they are not adjacent to each other in a naturally occurring protein or nucleic acid.
- Host cell refers to a naturally occurring cell or a transformed cell that contains a vector and supports the replication of the vector.
- Host cells may be cultured cells, explants, cells in vivo, and the like.
- Host cells may be prokaryotic cells such as E. coli, or eukaryotic cells such as yeast, insect, amphibian, or mammalian cells, such as CHO, HeLa.
- nucleic acids or polypeptide sequences means that the sequences have a specified percentage of nucleotides or amino acids that are the same over a specified region. The percentage may be calculated by comparing optimally aligning the two sequences, comparing the two sequences over the specified region, determining the number of positions at which the identical residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the specified region, and multiplying the result by 100 to yield the percentage of sequence identity.
- Label as used herein may mean a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means.
- useful labels include radioactive isotopes, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in an ELISA), biotin, digoxigenin, or haptens, green fluorescent protein, and other entities which can be made detectable.
- a label may be incorporated into nucleic acids and proteins at any position.
- linking refers to a chemical moiety that connects a molecule to another molecule, covalently links separate parts of a molecule or separate molecules.
- the linker provides spacing between the two molecules or moieties such that they are able to function in their intended manner.
- Examples of linking groups include peptide linkers, enzyme sensitive peptide linkers/linkers, self-immolative linkers, acid sensitive linkers, multifunctional organic linking agents, bifunctional inorganic
- linker may be stable or degradable/cleavable.
- nucleic acid refers to a polymer composed of a multiplicity of nucleotide units (ribonucleotide or deoxyribonucleotide or related structural variants) linked via phosphodiester bonds, including but not limited to, DNA or RNA.
- the term encompasses sequences that include any of the known base analogs of DNA and RNA. Examples of a nucleic acid include and are not limited to mRNA, miRNA, tRNA, rRNA, snRNA, siRNA, dsRNA, cDNA and DNA/RNA hybrids.
- Nucleic acids may be single stranded or double stranded, or may contain portions of both double stranded and single stranded sequence.
- the nucleic acid may be DNA, both genomic and cDNA, RNA, or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine and isoguanine.
- Nucleic acids may be obtained by chemical synthesis methods or by recombinant methods.
- a nucleic acid also encompasses the complementary strand of a depicted single strand.
- many variants of a nucleic acid may be used for the same purpose as a given nucleic acid.
- a nucleic acid also encompasses substantially identical nucleic acids and complements thereof.
- a single strand provides a probe for a probe that may hybridize to the target sequence under stringent hybridization conditions.
- a nucleic acid also encompasses a probe that hybridizes under stringent hybridization conditions.
- operable combination refers to the linkage of nucleic acid sequences in such a manner that a nucleic acid molecule capable of directing the transcription of a given gene and/or the synthesis of a desired protein molecule is produced.
- the term also refers to the linkage of amino acid sequences in such a manner so that a functional protein is produced.
- polypeptide in its broadest sense refers to a compound of two or more subunit amino acids, amino acid analogs or peptidomimetics.
- Probe refers to an oligonucleotide capable of binding to a target nucleic acid of complementary sequence through one or more types of chemical bonds, usually through complementary base pairing, usually through hydrogen bond formation. Probes may bind target sequences lacking complete complementarity with the probe sequence depending upon the stringency of the hybridization conditions. There may be any number of base pair mismatches which will interfere with hybridization between the target sequence and the single stranded nucleic acids of the present invention.
- a probe may be single stranded or partially single and partially double stranded. The strandedness of the probe is dictated by the structure, composition, and properties of the target sequence. Probes may be directly labeled or indirectly labeled such as with biotin to which a streptavidin complex may later bind. A probe may range in length from 5 nucleotides to a 1000 nucleotides in length, most preferably from 10 to 50 nucleotides in length.
- Promoter refers to a synthetic or naturally-derived molecule which is capable of conferring or activating expression of a nucleic acid in a cell.
- a promoter may comprise one or more specific regulatory elements to further enhance expression and/or to alter the spatial expression and/or temporal expression of same.
- a promoter may also comprise distal enhancer or repressor elements, which can be located as much as several thousand base pairs from the start site of transcription.
- a promoter may be derived from sources including viral, bacterial, fungal, plants, insects, and animals.
- a promoter may regulate the expression of a gene component constitutively, or differentially with respect to cell, the tissue or organ in which expression occurs or, with respect to the developmental stage at which expression occurs, or in response to external stimuli such as physiological stresses, pathogens, metal ions, or inducing agents.
- promoters include the bacteriophage T7 promoter, bacteriophage T3 promoter, SP6 promoter, lac operator-promoter, tac promoter, SV40 late promoter, SV40 early promoter, RSV-LTR promoter, CMV IE promoter, SV40 early promoter or SV40 late promoter and the CMV IE promoter.
- a "recombinant" peptide, polypeptide, or protein refers to a peptide, polypeptide, or protein produced by recombinant DNA techniques; i.e., produced from cells transformed by an exogenous DNA construct encoding the desired peptide, polypeptide, or protein.
- standard level refers to a control level of a particular protein expressed in samples of the same type of tissue or cells from subjects who do not have cancer; for example, a predetermined standard can be a control level determined based upon the expression of the HERV-WL gene in tissue isolated from subjects who do not have breast cancer.
- Selectable marker refers to any gene which confers a phenotype on a cell in which it is expressed to facilitate the identification and/or selection of cells which are transfected or transformed with a genetic construct.
- selectable markers include the ampicillin-resistance gene, tetracycline- resistance gene, bacterial kanamycin-resistance gene, zeocin resistance gene, the AURI-C gene which confers resistance to the antibiotic aureobasidin A, phosphinothricin-resistance gene, neomycin phosphotransferase gene (nptll), hygromycin-resistance gene, beta- glucuronidase (GUS) gene, chloramphenicol acetyltransferase (CAT) gene, green fluorescent protein-encoding gene and luciferase gene.
- Stringent hybridization conditions refers to conditions under which a first nucleic acid sequence (e.g., probe) will hybridize to a second nucleic acid sequence (e.g., target), such as in a complex mixture of nucleic acids, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. One with ordinary skill can determine the appropriate conditions according to standard assays known in the art.
- the term “subject” refers to any animal (e.g., a mammal), including, but not limited to humans, non-human primates, rodents, and the like, which is to be the recipient of a particular treatment.
- the terms “subject” and “patient” are used interchangeably herein in reference to a human subject.
- substantially complementary refers to that a first sequence is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identical to the complement of a second sequence over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50 or more nucleotides, or that the two sequences hybridize under stringent hybridization conditions.
- substantially identical refers to that a first and second sequence are at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98% or 99% identical over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50 or more nucleotides or amino acids, or with respect to nucleic acids, if the first sequence is substantially complementary to the complement of the second sequence.
- tumor refers to any mass of tissue that results from excessive cell growth or proliferation, either benign (noncancerous) or malignant (cancerous), including pre-cancerous lesions.
- Vector refers to a nucleic acid sequence containing an origin of replication.
- a vector may be a plasmid, bacteriophage, bacterial artificial chromosome, yeast artificial chromosome or a virus.
- a vector may be a DNA or RNA vector.
- a vector may be either a self-replicating extrachromosomal vector or a vector which integrates into a host genome.
- expression vector refers to a nucleic acid assembly containing a promoter which is capable of directing the expression of a sequence or gene of interest in a cell. Vectors typically contain nucleic acid sequences encoding selectable markers for selection of cells that have been transfected by the vector.
- vector construct refers to any nucleic acid construct capable of directing the expression of a gene of interest and which can transfer gene sequences to target cells or host cells.
- the present invention provides isolated antibodies that specifically bind to the human endogenous retrovirus env polypeptide (HERV-WL).
- SEQ ID NO: l is a nucleotide sequence that encodes the HERV-WL polypeptide.
- the antibody of the invention which is against HERV-WL, can be obtained by methods known in the art, for example by immunizing an animal with HERV-WL or an polypeptide selected from the amino acid sequence of HERV-WL to which an antibody of the invention specifically binds with measurable affinity, or an epitope selected within the HERV-WL polypeptide, and collecting and purifying the antibody produced in vivo according to a common procedure, known to those with skill in the art.
- the HERV-WL polypeptide contains a peptide region TEKVKEIRDGIQRRA (SEQ ID NO:2).
- Routine methods to produce HERV-WL polypeptide a polypeptide selected from the amino acid sequence of HERV-WL to which an antibody of the invention specifically binds with measurable affinity, or a polypeptide of SEQ ID NO:2 as an epitope on an antigen are known in the art.
- HERV-WL polypeptide a polypeptide selected from the amino acid sequence of HERV-WL to which an antibody of the invention specifically binds with measurable affinity, or a polypeptide of SEQ ID NO:2 can be used as an epitope on an antigen and an animal can be immunized with HERV-WL polypeptide, apolypeptide selected from the amino acid sequence of HERV-WL to which an antibody of the invention specifically binds with measurable affinity, or SEQ ID NO:2.
- the antigen may comprise an epitope that is substantially identical to HERV-WL polypeptide, a polypeptide selected from the amino acid sequence of HERV-WL to which an antibody of the invention specifically binds with measurable affinity, or a polypeptide of SEQ ID NO:2.
- the epitope may also be a conservatively modified variant of HERV-WL polypeptide, a polypeptide selected from the amino acid sequence of HERV-WL to which an antibody of the invention specifically binds with measurable affinity, or a polypeptide of SEQ ID NO:2.
- a monoclonal antibody can be obtained by fusing antibody-producing cells which produce an antibody against HERV-WL with myeloma cells to establish a hybridoma according to known methods (for example, Kohler and Milstein, Nature, (1975) 256, pp. 495-497; Kennet, R. ed., Monoclonal Antibodies, pp. 365-367, Plenum Press, N.Y. (1980)).
- the antibody of this invention also includes humanized HERV-WL antibodies.
- the use of transgenic mice carrying human immunoglobulin (Ig) loci in their germline configuration provide for the isolation of high affinity fully human monoclonal antibodies directed against a variety of targets including human self antigens for which the normal human immune system is tolerant (see for example Lonberg, N. et al., U.S. Pat. NO: 5,569,825, U.S. Pat. NO: 6,300,129; Kucherlapati, et al., U.S. Pat. NO: 6,713,610).
- the endogenous immunoglobulin loci in such mice can be disrupted or deleted to eliminate the capacity of the animal to produce antibodies encoded by endogenous genes.
- Antibodies obtained from non-human sources can be humanized.
- the humanized antibody can comprise portions derived from an immunoglobulin of nonhuman origin with the requisite specificity, such as a mouse, and from immunoglobulin sequences of human origin (e.g., chimeric immunoglobulin), joined together chemically by conventional techniques (e.g., synthetic) or prepared as a contiguous polypeptide using genetic engineering techniques (e.g., DNA encoding the protein portions of the chimeric antibody can be expressed to produce a contiguous polypeptide chain).
- a humanized immunoglobulin is one containing one or more immunoglobulin chains comprising a CDR derived from an antibody of nonhuman origin and a framework region derived from a light and/or heavy chain of human origin (e.g., CDR-grafted antibodies with or without framework changes).
- the framework adaptation process was based upon the similarity of framework regions between mouse mAb C836 and sequences in the human germline databases as essentially described in WO/08052108 A2 "Methods For Use In Human- Adapting Monoclonal Antibodies" where framework length is matched residue for residue to the parental variable or V-regions.
- Antibodies that bind to HERV-WL or an epitope selected within the HERV- WL polypeptide can be obtained using phage display technology.
- antibodies that bind to HERV-WL polypeptide, an arbitrary polypeptide selected from the amino acid sequence of HERV-WL, and SEQ ID NO:2 can also be obtained using phage display technology. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol.
- the present invention also includes nucleotide sequences that encode SEQ ID NO:2 and vectors that contain the nucleotide sequences that encode SEQ ID NO:2.
- a human HERV-WL antibody is selected from a phage library, where that phage comprises human immunoglobulin genes and the library expresses human antibody binding domains as, for example, single chain antibodies (scFv), as Fab, or some other construct exhibiting paired or unpaired antibody variable regions fused to one or more of the phage coat proteins.
- scFv single chain antibodies
- Fab fragment antigen binding domains
- Such phage display methods for isolating human antibodies are established in the art, see for example: U.S. Pat. Nos. 5,223,409; 5,403,484; and 5,571,698 to Ladner et al.; U.S. Pat. Nos.
- the antibodies that bind to HERV-WL and SEQ ID NO:2 may also be detectably labeled.
- labels include radioactive isotopes, enzymes, enzyme fragments, enzyme substrates, enzyme inhibitors, coenzymes, catalysts, fluorophores, dyes, chemiluminescers, luminescers, or sensitizers; a non-magnetic or magnetic particle, iodinated sugars that are used as radioopaque agents, and can be appended to a linker and conjugated to the antibody.
- agents may be conjugated to the antibodies of this invention with or without a linker, including a toxin and/or a therapeutic agent such as small molecules that are known in the art to treat cancer, for example including without being limited, monomethyl auristatin E (MMAE), capecitabine, daunorubicin, doxorubicin, methotrexate, and Mitomycin C.
- MMAE monomethyl auristatin E
- An "immunotoxin” is a hybrid molecule, created by conjugating an antibody to all or part of a toxin, generally the active component of the toxin.
- the present invention provides an immunotoxin, an HERV-WL antibody conjugated to a toxin.
- toxins include without being limited, plant toxins such as arericin, saporin, and pokeweed antiviral protein (PAP), which inactivate ribosomes; and single-chain bacterial toxins such as diphtheria toxin (DT) and Pseudomonas exotoxin (PE). More than one agent may be conjugated to the antibody.
- plant toxins such as arericin, saporin, and pokeweed antiviral protein (PAP), which inactivate ribosomes
- PAP pokeweed antiviral protein
- single-chain bacterial toxins such as diphtheria toxin (DT) and Pseudomonas exotoxin (PE).
- DT diphtheria toxin
- PE Pseudomonas exotoxin
- More than one agent may be conjugated to the antibody.
- BIOCONJUGATE TECHNIQUES Academic Press; 1st edition, Greg T. Hermanson, 1996) describes techniques for modifying or crosslinking
- This invention also provides methods to detect HERV-WL in a cell, methods to detecting cancer in a subject and methods to assess effectiveness of a treatment in a subject suffering from cancer, as well as monitor the treatment of the cancer.
- a subject having cancer or prone to it can be determined based on the expression levels, patterns, or profile of the HERV-WL gene, such as nucleic acids (e.g., mRNA, miRNA) or polypeptides in a biological sample from the subject compared to a standard level in a corresponding control sample, such as a non-cancerous sample.
- HERV- WL polypeptides and nucleic acids can be used as markers to indicate the presence or absence of cancer or the risk of having cancer, as well as to assess the prognosis of the cancer.
- Diagnostic and prognostic assays of the invention include methods for assessing the expression level of the HERV-WL nucleic acids or polypeptides.
- An HERV-WL antibody can be used to detect the HERV-WL polypeptides.
- a nucleotide sequence that is substantially complementary, and/or substantially identical to HERV-WL SEQ ID NO: l can be used to detect the expression level of HERV-WL.
- a nucleotide sequence that is at least 85% identical to SEQ ID NO: l can be used to detect the expression level of HERV- WL.
- a nucleotide sequence that is at least 99% identical to the nucleotide sequence encoded by SEQ ID NO:2 can be used to detect the expression level of HERV-WL.
- probes that are substantially identical or substantially complementary to SEQ ID NO: 1 can be used to identify HERV-WL, as well as probes that hybridize to HERV-WL under high stringency conditions. The methods and kits herein described allow one to detect the HERV-WL in a cell, the presence of cancer in a subject and monitor the effectiveness of a cancer treatment.
- An increased expression or presence of HERV-WL in a biological sample from a subject compared to a standard level in a control sample may be indicative that the subject has cancer. Also a relative decrease in the expression level of HERV-WL may be indicative of the decrease in the size of a tumor or growth of a cancer, further facilitating a clinician to determine whether a cancer treatment is effective.
- HERV-WL can be detected in a variety of cell types including without limitation producer cells including bone cells, muscle cells, placenta cells, endothelial cells, epithelial cells, epidermoid cells, glial cells, tumor cells, and cells derived from tumor cell lines, and cancer cells.
- producer cells including bone cells, muscle cells, placenta cells, endothelial cells, epithelial cells, epidermoid cells, glial cells, tumor cells, and cells derived from tumor cell lines, and cancer cells.
- the types of cells derived from cancers such as blood cancers, lymphoma, B cell lymphoma, non-Hodgkin's lymphoma, diffuse large B cell lymphoma, Burkitt's lymphoma, ameloblastoma, carcinomas including squamous cell carcinoma, mucoepidermoid carcinoma, ovarian cancer, cervical cancer, prostate cancer, and breast cancer.
- the presence, level, or absence of the HERV-WL nucleic acid or polypeptide in a biological sample can be evaluated by obtaining a biological sample from a subject and contacting the biological sample with a compound or an agent capable of detecting the HERV-WL polypeptide or HERV-WL nucleic acid (e.g., mRNA, miRNA or genomic DNA probe).
- a compound or an agent capable of detecting the HERV-WL polypeptide or HERV-WL nucleic acid e.g., mRNA, miRNA or genomic DNA probe.
- the level of expression of HERV-WL can be measured in a number of ways, including measuring the HERV-WL mRNA; or measuring the amount of HERV- WL polypeptide.
- RNA samples can be isolated from biological samples using any of a number of well-known procedures.
- biological samples can be lysed in a guanidinium-based lysis buffer, optionally containing additional components to stabilize the RNA.
- the lysis buffer can contain purified RNAs as controls to monitor recovery and stability of RNA from cell cultures. Examples of such purified RNA templates include the Kanamycin Positive Control RNA from PROMEGA (Madison, WI), and 7.5 kb Poly(A)-Tailed RNA from LIFE TECHNOLOGIES (Rockville, MD). Lysates may be used immediately or stored frozen at, e.g., -80°C.
- total RNA can be purified from cell lysates (or other types of samples) using silica-based isolation in an automation-compatible, 96-well format, such as the RNEASY purification platform (QIAGEN, Inc., Valencia, CA).
- RNA is isolated using solid-phase oligo-dT capture using oligo-dT bound to microbeads or cellulose columns. This method has the added advantage of isolating mRNA from genomic DNA and total RNA, and allowing transfer of the mRNA-capture medium directly into the reverse transcriptase reaction.
- Other RNA isolation methods are contemplated, such as extraction with silica-coated beads or guanidinium. Further methods for RNA isolation and preparation can be devised by one skilled in the art.
- RNAse inhibitors are optionally added to the crude samples.
- genomic DNA can contribute one or more copies of a target sequence, depending on the sample. In situations in which the target sequence is derived from one or more highly expressed genes, the signal arising from genomic DNA may not be significant. But for genes expressed at low levels, the background can be eliminated by treating the samples with DNAse, or by using primers that target splice junctions for subsequent priming of cDNA or amplification products. For example, one of the two target- specific primers could be designed to span a splice junction, thus excluding DNA as a template.
- the two target-specific primers can be designed to flank a splice junction, generating larger PCR products for DNA or unspliced mRNA templates as compared to processed mRNA templates.
- One skilled in the art could design a variety of specialized priming applications that would facilitate use of crude extracts as samples for the purposes of this invention.
- the level of mRNA corresponding to HERV-WL in a cell can be determined both in situ and in vitro.
- Messenger RNA isolated from a biological sample can be used in hybridization or amplification assays that include, Southern or Northern analyses, PCR analyses, and probe arrays.
- a preferred diagnostic method for the detection of mRNA levels involves contacting the isolated mRNA with a nucleic acid probe that can hybridize to the mRNA encoded by HERV-WL.
- the HERV-WL probe can be a full-length nucleic acid, for example SEQ ID NO: 1 or a portion thereof, for example the nucleotide sequence encoded by SEQ ID NO 2, an oligonucleotide of at least 10 nucleotides in length and sufficient to specifically hybridize under stringent conditions to the mRNA.
- mRNA (or cDNA prepared from it) is immobilized on a surface and contacted with the probes, for example, by running the isolated mRNA on an agarose gel and transferring the mRNA from the gel to a membrane, such as nitrocellulose.
- the probes are immobilized on a solid support and the mRNA (or cDNA) is contacted with the probes, for example, in a polynucleotide chip array.
- a skilled artisan can adapt known mRNA detection methods for detecting the level of an mRNA.
- the level of mRNA (or cDNA prepared from it) in a sample encoded by HERV-WL to be examined can be evaluated with nucleic acid amplification, e.g., by standard PCR (U.S. Patent NO: 4,683,202), RT-PCR (Bustin S. J Mol Endocrinol. 25: 169- 93, 2000), quantitative PCR (Ong Y. et al., Hematology. 7:59-67, 2002), real time PCR (Ginzinger D. Exp Hematol. 30:503-12, 2002), and in situ PCR (Thaker V. Methods Mol Biol. 115:379-402, 1999), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques known in the art.
- primer refers to any nucleic acid that is capable of hybridizing at its 3' end to a complementary nucleic acid molecule, and that provides a free 3' hydroxyl terminus which can be extended by a nucleic acid polymerase.
- amplification primers are a pair of nucleic acid molecules that can anneal to 5' or 3' regions of a gene (plus and minus strands, respectively, or vice-versa) and contain a short region in between. Under appropriate conditions and with appropriate reagents, such primers permit the amplification of a nucleic acid molecule having the nucleotide sequence flanked by the primers.
- a cell or tissue sample can be prepared and immobilized on a support, such as a glass slide, and then contacted with a probe that can hybridize to mRNA.
- a probe that can hybridize to mRNA.
- Alternative methods for amplifying nucleic acids corresponding to expressed RNA samples include those described in, e.g., U.S. Patent NO: 7,897,750.
- the methods of the invention further include contacting a control sample with a compound or agent capable of detecting the mRNA of HERV-WL and comparing the presence of the mRNA in the control sample with the presence of the RNA in the biological sample.
- the above-described nucleic acid-based diagnostic methods can provide qualitative and quantitative information to determine whether a subject has a disease characterized by cancer or the effectiveness of a cancer treatment.
- An increased expression or presence of HERV-WL in a biological sample from a subject compared to a standard level in a control sample may be indicative that the subject has cancer.
- a relative decrease in the expression level of HERV-WL may be indicative of the decrease in the size of a tumor or growth of a cancer.
- the types of cancer include without limitation blood cancers, lymphoma, B cell lymphoma, non-Hodgkin's lymphoma, diffuse large B cell lymphoma, Burkitt's lymphoma, carcinomas, including squamous cell carcinoma and mucoepidermoid carcinoma, cervical cancer, prostate cancer,, ovarian cancer and breast cancer.
- a variety of methods can be used to determine the level of the HERV-WL polypeptide disclosed herein. In general, these methods include contacting an agent that selectively binds to the polypeptide, such as an antibody, to evaluate the level of polypeptide in a sample.
- Antibodies can be polyclonal, or monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab')2) can also be used. In a preferred embodiment, the antibody bears a detectable label.
- a label may be incorporated into the polypeptide at any position.
- the term "labeled”, with regard to the antibody, is intended to encompass direct labeling of the probe or antibody by physically linking a detectable substance to the probe or antibody, as well as indirect labeling of the antibody by reactivity with a detectable substance.
- an antibody with a rabbit Fc region can be indirectly labeled using a second antibody directed against the rabbit Fc region, wherein the second antibody is coupled to a detectable substance.
- detectable substances include radio isotopes (e.g., 1251, 1311, 35S, 3H, or 32P), enzymes (e.g., alkaline phosphatase, horseradish peroxidase, luciferase, or ⁇ -glactosidase), fluorescent moieties or proteins (e.g., fluorescein, rhodamine, phycoerythrin, Green Flourescent Protein (GFP), or Blue Fluorescent Protein (BFP)), or luminescent moieties (e.g., QdotTM nanoparticles by the Quantum Dot Corporation, Palo Alto, CA).
- radio isotopes e.g., 1251, 1311, 35S, 3H, or 32P
- enzymes e.g., alkaline phosphat
- the detection methods can be used to detect a polypeptide in a biological sample in vitro as well as in vivo.
- In vitro techniques for detection of the polypeptide include ELISAs, immunoprecipitations, immunofluorescence, immunohistochemistry; immunocytochemistry; flow cytometry; antibody arrays and Western blotting analysis. Such techniques are commonly known in the art.
- In vivo techniques for detection of the polypeptide include introducing into a subject a labeled HERV-WL antibody.
- the antibody can be labeled with a detectable substance as described above. The presence and location of the detectable substance in a subject can be detected by standard imaging techniques.
- An ELISA short for Enzyme-Linked Immunosorbent Assay, is a biochemical technique to detect the presence of an antibody or an antigen in a sample. It utilizes a minimum of two antibodies, one of which is specific to the antigen and the other of which is coupled to an enzyme. The second antibody will cause a chromogenic or fluorogenic substrate to produce a signal. Variations of ELISA include sandwich ELISA, competitive ELISA, and ELISPOT. Because the ELISA can be performed to evaluate either the presence of antigen or the presence of antibody in a sample, it is a useful tool both for determining serum antibody concentrations and also for detecting the presence of antigen.
- Immunohistochemistry and immunocytochemistry refer to the process of localizing proteins in a tissue section or cell, respectively, via the principle of antigens in tissue or cells binding to their respective antibodies. Visualization is enabled by tagging the antibody with color producing or fluorescent tags. Typical examples of color tags include, but are not limited to, horseradish peroxidase and alkaline phosphatase. Typical examples of fluorophore tags include, but are not limited to, fluorescein isothiocyanate (FITC) or phycoerythrin (PE).
- FITC fluorescein isothiocyanate
- PE phycoerythrin
- Flow cytometry is a technique for counting, examining and sorting microscopic particles suspended in a stream of fluid. It allows simultaneous multiparametric analysis of the physical and/or chemical characteristics of single cells flowing through an optical/electronic detection apparatus.
- a beam of light e.g., a laser
- a number of detectors are aimed at the point where the stream passes through the light beam; one in line with the light beam (Forward Scatter or FSC) and several perpendicular to it (SSC) and one or more fluorescent detectors).
- Each suspended particle passing through the beam scatters the light in some way, and fluorescent chemicals in the particle may be excited into emitting light at a lower frequency than the light source.
- the combination of scattered and fluorescent light is picked up by the detectors, and by analyzing fluctuations in brightness at each detector, one for each fluorescent emission peak, it is possible to deduce various facts about the physical and chemical structure of each individual particle.
- FSC correlates with the cell volume and SSC correlates with the density or inner complexity of the particle (e.g., shape of the nucleus, the amount and type of cytoplasmic granules or the membrane roughness).
- the diagnostic methods described herein to detect HERV-WL polypeptides in a biological sample from a subject can identify subjects having, or at risk of developing cancer, or the effectiveness of cancer treatment.
- An increased expression or presence of HERV-WL in a biological sample from a subject compared to a standard level in a control sample may be indicative that the subject has cancer.
- a relative decrease in the expression level of HERV-WL may be indicative of the decrease in the size of a tumor or growth of a cancer.
- the types of cancer include without limitation blood cancers, lymphoma, B cell lymphoma, non-Hodgkin's lymphoma, diffuse large B cell lymphoma, Burkitt's lymphoma, carcinomas including squamous cell carcinoma, mucoepidermoid carcinoma, ovarian cancer, cervical cancer, prostate cancer, and breast cancer.
- the present invention provides an isolated nucleic acid comprising a nucleotide sequence referred to in SEQ ID NO: l and the nucleotide sequence that encodes SEQ ID NO: 2 or variants thereof.
- the variant may be a complement of the referenced nucleotide sequence.
- the variant may also be a nucleotide sequence that is substantially identical to the referenced nucleotide sequence or the complement thereof.
- the variant may also be a nucleotide sequence which hybridizes under stringent conditions to the referenced nucleotide sequence, complements thereof, or nucleotide sequences substantially identical thereto.
- the nucleic acid may have a length of from 10 to 1700 nucleotides.
- the nucleic acid may have a length of at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 60, 70, 80 or 90 nucleotides.
- the nucleic acid may be synthesized or expressed in a cell (in vitro or in vivo) using a vector described below.
- the nucleic acid may be synthesized as a single strand molecule and hybridized under stringent hybridization conditions to a substantially complementary nucleic acid to form a duplex, which is considered a nucleic acid of the invention.
- the nucleic acid may be introduced to a cell, tissue or organ in a single- or double- stranded form or capable of being expressed by a vector using methods well known to those skilled in the art.
- MOLECULAR CLONING A LABORATORY MANUAL (3rd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 2001) describes commonly used techniques in molecular biology.
- nucleic acid for example deletions, insertions, and/or substitutions in the sequence, which cause for so-called “silent changes", are considered to be part of the invention.
- nucleic acids of the present invention comprise also such nucleic acid sequences which contain sequences in essence equivalent to the nucleic acids described in SEQ ID NOs. 1 and 2.
- nucleic acids can show for example at least about 70%, more typically at least about 85%, 90% or 95% sequence identity to the nucleic acid sequences of SEQ ID NOs. 1 and a nucleotide sequence that encodes the polypeptide of SEQ ID NO:2.
- the present invention provides a vector comprising a nucleic acid comprising a sequence which is at least 85% identical to SEQ ID NO: l.
- the present invention also provides a vector comprising a nucleic acid comprising a sequence that encodes a peptide sequence that is at least 85% identical to SEQ ID NO:2.
- the present invention also provides a vector comprising a nucleic acid which hybridizes to the nucleic acid of SEQ ID NO: l and or a nucleotide sequence that encodes the polypeptide of SEQ ID NO:2 under high stringency conditions.
- An expression vector may comprise additional elements.
- the expression vector may have two replication systems allowing it to be maintained in two organisms, e.g., in mammalian or insect cells for expression and in a prokaryotic host for cloning and amplification.
- the expression vector may contain at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct.
- the integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector.
- the vector may also comprise a selectable marker to allow the selection of transformed host cells.
- the present invention provides a host cell comprising a vector of the invention.
- the cell may be a bacterial, fungal, plant, insect or animal cell.
- Methods are known in the art to introduce the nucleic acids of the present invention to a host cell, including electroporation and standard methods of transfection.
- MOLECULAR CLONING A LABORATORY MANUAL (3rd Ed., ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 2001) describes commonly used techniques in molecular biology.
- the present invention provides an isolated polypeptide comprising a sequence encoded by SEQ ID NO: l, or having the sequence of SEQ ID NO:2 or variants thereof.
- polypeptides can show for example at least about 70%, more typically at least about 85%, 90% or 95% sequence identity to the polypeptide sequences described in SEQ ID NOs. 1 and 2.
- the variants of the invention can be operatively linked to a polypeptide not according to the invention (e.g., heterologous amino acid sequences) to form fusion proteins.
- a polypeptide not according to the invention in this context refers to a polypeptide having an amino acid sequence corresponding to a polypeptide which is not substantially identical to a variant HERV-WL of the invention.
- the variant of the invention can correspond to a full length sequence.
- the polypeptide not according to the invention can be fused to the N- terminus or C-terminus of the variant polypeptide.
- the fusion protein is a fusion protein in which the variant sequence/s is/are fused to the C- terminus of the GST sequences.
- Such fusion proteins can facilitate the purification of a recombinant variant according to the invention.
- the fusion protein is a variant of the invention containing a heterologous signal sequence at its N-terminus.
- expression and/or secretion of a variant of the invention can be increased through use of a heterologous signal sequence.
- the gp67 secretory sequence of the baculovirus envelope protein can be used as a heterologous signal sequence (Current Protocols in Molecular Biology, Ausubel et al., eds., John Wiley & Sons, 1992).
- Other examples of eukaryotic heterologous signal sequences include the secretory sequences of melittin and human placental alkaline phosphatase (Stratagene; La Jolla, Calif.).
- useful prokarytic heterologous signal sequences include the phoA secretory signal (Sambrook et al., supra) and the protein A secretory signal (Pharmacia Biotech; Piscataway, N.J.).
- a signal sequence can be used to facilitate secretion and isolation of a variant of the invention.
- Signal sequences are typically characterized by a core of hydrophobic amino acids, which are generally cleaved from the mature protein during secretion in one or more cleavage events.
- Such signal peptides contain processing sites that allow cleavage of the signal sequence from the mature proteins as they pass through the secretory pathway.
- the signal sequence may direct secretion of the variant, such as from a eukaryotic host into which the expression vector is transformed, and the signal sequence may then be subsequently or concurrently cleaved.
- the variant of the invention may then be readily purified from the extracellular medium by known methods.
- the signal sequence can be linked to the variant of interest using a sequence, which facilitates purification, such as with a GST domain.
- the sequence encoding the variant of the invention may be fused to a marker sequence, such as a sequence encoding a peptide, which facilitates purification of the fused variant of the invention.
- the marker sequence is a hexa- histidine peptide, such as the tag provided in a pQE vector (Qiagen, Inc.), among others, many of which are commercially available. As described in Gentz et al, Proc. Natl. Acad. Sci.
- hexa-histidine provides for convenient purification of the fusion protein.
- the HA tag is another peptide useful for purification which corresponds to an epitope derived of influenza hemaglutinin protein, which has been described by Wilson et al., Cell37:767 (1984), for instance.
- the present invention provides a kit comprising one or more detection reagents which specifically bind to a HERV-WL polypeptide.
- the kit includes an antibody that binds to the polypeptide encoded by SEQ ID NO: l or the polypeptide of SEQ ID NO:2.
- the detection reagents may be peptide sequences known to flank the HERV-WL antibodies which bind to the HERV-WL polypeptides.
- the reagents may be bound to a solid matrix or packaged with reagents for binding them to the matrix.
- the solid matrix or substrate may be in the form of beads, plates, tubes, dip sticks, strips or biochips. Biochips or plates with addressable locations and discreet microtitre plates are particularly useful.
- Detection reagents include wash reagents and reagents capable of detecting bound antibodies (such as labeled secondary antibodies), or reagents capable of reacting with the labeled antibody.
- the kit will also conveniently include a control reagent (positive and/or negative) and/or a means for detecting the antibody. Instructions for use may also be included with the kit. Most usually, the kits will be formatted for assays known in the art, for example, ELISA assays, as are known in the art.
- the kit may be comprised of one or more containers and may also include collection equipment, for example, bottles, bags (such as intravenous fluids bags), vials, syringes, and test tubes. Other components may include needles, diluents and buffers.
- the kit may include at least one container comprising a pharmaceutically- acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution.
- the kit may be customized for use in various antibody binding assays, such as competitive binding assays, non-competitive assays, direct and indirect sandwich assays, ELISAs, fluoroimmunoassays, immunoradiometric assays, luminescence assays, chemiluminesence assays, enzyme linked immunofluorescent assays (ELIFA), immunoprecipitation assays, immunohistochemistry; immunocytochemistry; and flow cytometry.
- ELIFA enzyme linked immunofluorescent assays
- the present invention provides nucleotide sequences to identify nucleotide sequences that encode the HERV-WL polypeptide in a biological sample.
- Such nucleotide sequences include SEQ ID NO: l and a nucleotide sequence encoding the polypeptide of SEQ ID NO:2, and fragments thereof, and the complement of SEQ ID NO: l and a nucleotide sequence encoding the polypeptide of SEQ ID NO:2, and fragments thereof, and sequences that hybridize to the foregoing sequences under high stringency conditions, and the primers disclosed herein.
- One with ordinary skill in the art using common recombinant methods can determine the nucleotide sequences to be used to detect a nucleotide that encodes the HERV-WL polypeptide.
- kits to determine the presence of HERV-WL in a biological sample.
- a kit may contain a nucleic acid described herein together with any or all of the following: assay reagents, buffers, probes and/or primers, and sterile saline or another pharmaceutically acceptable emulsion and suspension base.
- the kit may include instructional materials containing directions (e.g., protocols) for the practice of the methods described herein.
- the kit may be a kit for the amplification, detection, identification or quantification of a target HERV-WL mRNA sequence.
- the kit may contain a poly(T) primer, a forward primer, a reverse primer, and a probe.
- a kit of the invention includes one or more microarray slides (or alternative microarray format) onto which a plurality of different nucleic acids (each corresponding to different regions or nucleic acid variants of HERV-WL) have been deposited.
- the kit can also include a plurality of labeled probes.
- the kit can include a plurality of nucleotide sequences suitable as probes and a selection of labels suitable for customizing the included nucleotide sequences, or other nucleotide sequences at the discretion of the practitioner.
- at least one included nucleotide sequence corresponds to a control sequence, e.g., a "housekeeping" gene, ⁇ -actin or the like.
- Exemplary labels include, but are not limited to, a fluorophore, a dye, a radiolabel, an enzyme tag, that is linked to a nucleic acid primer.
- kits that are suitable for amplifying nucleic acid corresponding to the expressed RNA samples are provided.
- a kit includes reagents and primers suitable for use in any of the amplification methods described above.
- the kits are suitable for amplifying a signal corresponding to hybridization between a probe and a target nucleic acid sample (e.g., deposited on a microarray).
- kits one or more materials and/or reagents required for preparing a biological sample for HERV-WL expression analysis are optionally included in the kit.
- one or more enzymes suitable for amplifying nucleic acids including various polymerases (RT, Taq, etc.), one or more deoxynucleotides, and buffers to provide the necessary reaction mixture for amplification.
- kits are employed for analyzing HERV-WL expression patterns using mRNA as the starting template.
- the mRNA template may be presented as either total cellular RNA or isolated mRNA; both types of sample yield comparable results.
- the methods and kits described in the present invention allow quantitation of other products of gene expression, including tRNA, rRNA, or other transcription products.
- kits of the invention further include software to expedite the generation, analysis and/or storage of data, and to facilitate access to databases.
- the software includes logical instructions, instructions sets, or suitable computer programs that can be used in the collection, storage and/or analysis of the data. Comparative and relational analysis of the data is possible using the software provided.
- cDNA was synthesized using Superscript II reagents (Invitrogen Life Technologies, Carlsbad, CA, USA).
- HERV-W-env (HERV-W) and TATA-binding protein (TBP) mRNA levels were measured in triplicate samples by real-time quantitative PCR (QPCR), with SYBR green detection on iCycler iQ (Bio-Rad, Hercules, CA, USA).
- TBP was used as a "house-keeping gene" for normalization of HERV-W mRNA expression.
- Comparative threshold cycle (CT) was used to determine mRNA expression of HERV-W and TBP, relative to no template control.
- the forward and reverse (5'-3') PCR primers used for HERV-W (designed from GenBank accession # AF072506) were CTTAGTGCCCCCTATGACCA (SEQ ID NO: 3) and
- CCDS5315.1 were AACAACAGCCTGCCACCTTACG (SEQ ID NO: 5) and
- HERV-WL Human diffuse large B cell lymphoma cells, expressing high levels of human endogenous retroviral envelope protein, were used as a source to clone endogenous retroviral protein (HERV-WL). Based on the HERV-W-env mRNA expression profile in human DLCL cells that were screened, CRL2631 DLCL has the most HERV-W mRNA expression. cDNA from CRL2631 was used to amplify HERV-env full length coding sequence. The forward and reverse primers (5 '-3') used were
- ATGGCCCTCCCTTATCAT (SEQ ID NO: 7 )and CTAACTGCTTCCTGCTGA (SEQ ID NO: 8) (respectively).
- Easy-A high-fidelity enzyme (Stratagene, La Jolla, CA) was used to avoid the introduction of mutation during PCR reaction.
- PCR product was then cloned into TOPO TA vector (Life Technologies, Carlsbad, CA), clones were sequenced.
- One clone which had the correct insert hereinafter named HERV-WL was sub cloned into expression vector pDual GC (Stratagene) for bacteria expression.
- HERV-WL The sequence of the HERV-WL cloned from GC-derived B cell lymphoma was somewhat similar to the previously described syncytin- 1 (HERV-W) which mediates cell-cell fusions of cytotrophoblasts into syncytiotrophoblasts.
- HERV-WL had 93% nucleotide identity compared to HERV-W.
- HERV-WL has 2 translation frames ( Figure 6A and 6B).
- HERV-WL translation frame 1 has The forward and reverse primers (5 '-3') used for cloning into pDual GC were AACTCTTCAATGGCCCTCCCTTATCAT (SEQ ID NO: 9) and CTAACTGCTTCCTGCTGA (SEQ ID NO: 10) (respectively).
- the plasmid used for expression in human cells was pIRES/EGFP (Stratagene); and the forward and reverse primers (5 '-3') used for this cloning were TAGAATTC ATGGCCCTCCCTTATCAT (SEQ ID NO: 11) and AAGTCGACCTAACTGCTTCCTGCTGA (SEQ ID NO: 12) (respectively).
- the clones of pDual GC with HERV-WL inserts were screened using the same primers used for the cloning (as stated above).
- pDual GC vector has a coding sequence for his6 tag and a stop codon after the his6 tag at the 3' end of the insertion sequence.
- the expression vector with the correct coding sequence for HERV-WL (now referred to as pDual GC_HERV-WL_His6) was transformed into BL21 ( DE3) cells, HERV-WL-His6 recombinant protein expression was induced by adding IPTG to the culture.
- HERV-WL-His6 recombinant protein was purified by using Ni-NTA Superflow Columns (Qiagen Valencia, CA). The protein was dialyzed and concentrated to 2.5mg/ml.
- This protein was used to immunize rabbits and mice to produce rabbit polyclonal and mouse monoclonal antibodies, respectively.
- a fifteen-mer carboxyl terminal amino acid sequence (N' -TEKVKEIRDGIQRRA-C, SEQ ID NO:2) of HERV-WL was used to produce rabbit anti-peptide antibody.
- the rabbit antibodies were purified by passing twice over pure HERV-WL affinity column.
- the polyclonal anti-HERV-WL Abs were affinity purified, the detection of surface HERV-WL was greatly enhanced.
- the following cell lines were detected by anti-HERV-WL Abs: CRL2630, CRL2631, RL, DB, and HT are DLCL lines; Raji and Ramos are Burkitt's lymphoma cell lines; and L540 is a Hodgkin's- derived cell line.
- lymphoma cell lines for surface expression of HERV-WL using mouse monoclonal anti-HERV-WL antibody indicated that HERV-WL can be detected on the surface of lymphoma cells.
- Mouse ascites fluid of anti-HERV-WL was used together with PE-conjugated goat anti-mouse F(ab')2 (as secondary antibody).
- the use of pure expressed HERV-WL protein as a blocking agent in intracellular staining of lymphoma cells showed that the mAb is, indeed, specific for HERV-WL, see Figure 3.
- the blocking reagent was able to reduce the level of HERV-WL in lymphoma cells to that of normal human B cell.
- Purified IgG of anti-HERV-WL mAb was used together with PE-conjugated goat anti-mouse F(ab')2 (as secondary antibody) to detect intracellular expression of HERV-WL in DLCL lymphoma (CRL2630), compared with normal human B cells.
- PE-conjugated goat anti-mouse F(ab')2 as secondary antibody
- the use of pure HERV-WL protein as a blocking reagent was able to bring down the detection of HERV-WL in lymphoma cells to a level comparable to that detected in normal B cells.
- HERV-WL expression might be detected by histology in human cancer
- 20 archived oral squamous cell carcinoma specimens were examined by immunohistochemistry, using affinity purified rabbit polyclonal anti-HERV-WL IgG antibody.
- the samples were deparaffinized, and the antigen was retrieved using 0.1M citrate buffer (pH 6.0). After peroxidase block, the slides coated with the samples were stained using biotinylated link followed by strepavidin-HRP, and hemnatoxylin counter stain.
- HERV-WL was detected in mucoepidermoid carcinoma (MEC) by
- HERV-WL was detected in ameloblastoma by immunohistochemistry by polyclonal anti-HERV-WL staining compared with normal epithelium. Ten out of ten ameloblastoma samples showed variable expression of HERV-WL in benign ameloblastoma tumor cells, with stronger expression in the tumor periphery at the interface with the connective tissue stroma.
- Human serum was taken from 2 non-Hodgkin's lymphoma patients, 2 ovarian cancer patients, 2 breast cancer patients (hNLBCSRM), 2 cervical cancer patients (hNLCCSRM), and 2 prostate cancer patients, and human saliva from 2 non-Hodgkin's lymphoma patients and 2 ovarian cancer patients.
- HERV-WL is increased in Ovarian Cancer, Breast Cancer and Non-Hodgkin's Lymphoma:
- Figure 4 depicts the detection of HERV-WL protein in serum samples from normal and cancer patients.
- the ELISA test revealed over-expression of HERV-WL in serum samples of a variety of human cancers, including no-Hodgkin's lymphoma, ovarian cancer and breast cancer.
- Figure 5 depicts the detection of HERV-WL protein in saliva samples from normal and cancer patients.
- Three normal saliva (hNLSLV) samples and one ovarian cancer (hOCSLV) did not have detectable HEV-WL.
- hNHSLV2 One non-Hodgkin's Lymphoma
- Values represent means (+SEM) of triplicate determinations.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention se rapporte à des polypeptides d'enveloppe de rétrovirus endogène humain (HERV-WL), à des séquences de nucléotides, à des anticorps HERV-WL. L'invention se rapporte d'autre part à des procédés de détection du cancer. L'invention se rapporte en outre à des procédés adaptés pour déterminer l'efficacité du traitement anticancer.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/198,201 US20140256583A1 (en) | 2011-03-01 | 2014-03-05 | Detection of human endogenous retrovirus expression in cancer and normal cells |
US15/495,627 US10370417B2 (en) | 2011-03-01 | 2017-04-24 | Methods for the diagnosis of cancer through detection of human endogenous retrovirus WL (HERV-WL) envelope expression |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161447750P | 2011-03-01 | 2011-03-01 | |
US61/447,750 | 2011-03-01 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14001304 A-371-Of-International | 2012-03-01 | ||
US14/198,201 Continuation US20140256583A1 (en) | 2011-03-01 | 2014-03-05 | Detection of human endogenous retrovirus expression in cancer and normal cells |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012118974A2 true WO2012118974A2 (fr) | 2012-09-07 |
WO2012118974A3 WO2012118974A3 (fr) | 2012-10-26 |
Family
ID=46758496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/027289 WO2012118974A2 (fr) | 2011-03-01 | 2012-03-01 | Détection d'expression de rétrovirus endogène humain dans des cellules cancéreuses et des cellules saines |
Country Status (2)
Country | Link |
---|---|
US (1) | US20140256583A1 (fr) |
WO (1) | WO2012118974A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014116958A1 (fr) * | 2013-01-25 | 2014-07-31 | Regents Of The University Of Minnesota | Compositions et procédés impliquant des protéines rétrovirales endogènes |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050196754A1 (en) * | 2000-03-31 | 2005-09-08 | Drmanac Radoje T. | Novel nucleic acids and polypeptides |
US20100074894A1 (en) * | 2007-02-09 | 2010-03-25 | Geneuro Sa | Pharmaceutical composition containing antibodies directed against the herv-w envelope |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2865403B1 (fr) * | 2004-01-23 | 2009-06-12 | Biomerieux Sa | Composition pour le traitement d'une pathologie associee a la msrv/herv-w |
-
2012
- 2012-03-01 WO PCT/US2012/027289 patent/WO2012118974A2/fr active Application Filing
-
2014
- 2014-03-05 US US14/198,201 patent/US20140256583A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050196754A1 (en) * | 2000-03-31 | 2005-09-08 | Drmanac Radoje T. | Novel nucleic acids and polypeptides |
US20100074894A1 (en) * | 2007-02-09 | 2010-03-25 | Geneuro Sa | Pharmaceutical composition containing antibodies directed against the herv-w envelope |
Non-Patent Citations (1)
Title |
---|
MARSDEN ET AL.: 'Short communication: Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophages.' AIDS RES. HUM. RETROVIRUSES. vol. 24, no. 11, November 2008, pages 1399 - 1404 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014116958A1 (fr) * | 2013-01-25 | 2014-07-31 | Regents Of The University Of Minnesota | Compositions et procédés impliquant des protéines rétrovirales endogènes |
US9878002B2 (en) | 2013-01-25 | 2018-01-30 | Regents Of The University Of Minnesota | Compositions and methods involving endogenous retrovirus proteins |
Also Published As
Publication number | Publication date |
---|---|
WO2012118974A3 (fr) | 2012-10-26 |
US20140256583A1 (en) | 2014-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2644686C2 (ru) | Идентификация опухолеассоциированных антигенов для диагностики и терапии | |
US10202605B2 (en) | Methods of identifying and treating poor-prognosis cancers | |
JP2007528737A (ja) | Mn/caix/ca9及び腎臓癌の予後診断 | |
EP2523687B1 (fr) | Procédés pour le diagnostic et le traitement de lymphomes cutanés à cellules T ciblant le récepteur NKp46 | |
JP7328641B2 (ja) | 悪性リンパ腫又は白血病の罹患の有無の判別方法並びに白血病の治療及び/又は予防のための薬剤 | |
KR101652962B1 (ko) | 돼지열병 바이러스 생마커백신주 접종 돼지와 돼지열병 바이러스 야외주 감염 돼지의 항체 감별용 키트 및 이를 이용한 감별방법 | |
US20230357394A1 (en) | Anti-human lag-3 antibodies and their use in immunohistochemistry (ihc) | |
US7902347B2 (en) | Human Ron-related gene variant associated with cancers | |
US10370417B2 (en) | Methods for the diagnosis of cancer through detection of human endogenous retrovirus WL (HERV-WL) envelope expression | |
CN111316102A (zh) | 使用甲硫氨酰-tRNA合成酶诊断胰腺癌的方法以及利用其的胰腺癌诊断试剂盒 | |
WO2006123829A1 (fr) | ANTICORPS DIRIGE CONTRE PAP2a ET SON UTILISATION DANS DES BUTS DE DIAGNOSTIC ET THERAPEUTIQUES | |
US20140256583A1 (en) | Detection of human endogenous retrovirus expression in cancer and normal cells | |
KR102058150B1 (ko) | 담도 세포에서 메티오닐-티알엔에이 합성효소를 이용한 담도암 진단 방법 | |
EP2148932A1 (fr) | Expression de sox11 dans des lymphomes malins | |
CN106957367B (zh) | 抗idh1 r132h抗体及其制备方法和用途 | |
CN112851818B (zh) | 针对d-二聚体的结合蛋白及其应用和检测d-二聚体的方法 | |
US20070264651A1 (en) | Methods, compositions, and kits for the detection and monitoring of kidney cancer | |
JPH08500731A (ja) | 診断法 | |
US20080108070A1 (en) | Methods, compositions, and kits for the detection and monitoring of colon cancer | |
WO2014185466A1 (fr) | Procédé d'évaluation du pronostic du cancer du pancréas | |
JP3888695B2 (ja) | ヒトlect2に対する抗体、それを産生する細胞、その測定法及び測定用キット | |
CN112739826A (zh) | 抗体-药物缀合物的敏感性标志物 | |
CN115028689B (zh) | 特异性检测hpv6和hpv11的双特异性检测试剂盒 | |
US10745701B2 (en) | Methods of identifying and treating poor-prognosis cancers | |
US20040138161A1 (en) | Methods of modulating proliferative conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12751751 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12751751 Country of ref document: EP Kind code of ref document: A2 |